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SUMMARY 
Three polymorphic sites of the apolipoprotien B gene in Chinese 
geriatric subjects were studied by polymerase chain reactions. 
They were the signal peptide insertion/deletion allele (Leu-Ala-
Leu -16/-14), the Xbal�site in exon 26 (Thr 2488) and the 
EcoRI site in exon 29 (Glu 4154/Lys). Cord blood samples from 
deliveries of normal Chinese infants were used to establish the 
allelic frequencies at these sites of the Chinese population. The 
study subjects, age range 57-87, were divided into the case 
group, having total serum cholesterol > 6.2 mmoL/L and LDL 
cholesterol > 4.1 imnoL/L, and the control group, total 
cholesterol < 6.2 mmoL/L and the LDL cholesterol < 4.1 mmoL/L. 
In the cord blood DNA analysis, there was no sex difference in 
the frequencies of the rare alleles: the D allele (deletion 
allele), the X+ allele (presence of the Xbal site) and E- allele 
(absence of the EcoRI site)• The results were consistent with 
published data on Chinese. There was significant difference 
between the cord blood samples and the control subjects in 
frequencies of the D allele, 0.181 vs 0.312, and the E- allele, 
0.061 vs 0.413. While the cord blood samples were different with 
the case subjects only in the D frequency, 0.181 vs 0.267. The 
D and the E- frequencies were unexpectedly higher in the controls 
than the cases, 0.312 vs 0.267 and 0.413 vs 0.067 respectively. 
The pattern of the frequency distribution of the genotype of the 
insertion/deletion region (II, ID, DD) and of the Xba I site 
(X-X-， X-X+, X+X+) were similar between the controls and the cord 
blood samples, but were different with the case subjects. The 
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genotypic pattern of the EcoRI site (E+E+, E+E-, E-E-) was 
different between the control and the cord blood samples, but 
similar between the latter and the case subjects. The only X+ 
allele found was in two X-X+ control subjects. There were no X+X+ 
genotype detected in both controls and cases. Presence of the D 
allele did not correlate with an increase in serum lipid levels 
in both control and case subjects. Case subjects having the E+E-
genotype had higher total serum cholesterol, triglyceride and 
LDL-cholesterol but lower HDL-cholesterol than those case 
subjects having the E+E+ genotype. In the control subjects, such 
relationships were reversed. The view that presence of the D and 
the X+ alleles was associated with increase in serum cholesterol 
levels was not affirmed by the results of this study. The 
conflicting effects of the E- allele on the lipid levels in the 
controls and cases cast a question on a positive relationship 
between E- and serum cholesterol. It is possible that the 
genotypic pattern of these three polymorphic sites of the 
apolipoprotein B gene and their effects on serum lipid levels are 
unique among Chinese geriatric subjects. This study also 
suggested that cord blood samples can be used to obtain reference 
genotypic patterns of the apolipoprotein B gene in a population. 
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1. INTRODUCTION 
Coronary heart disease (CHD) is a major public health problem in 
many industrialized countries. Although it is a multifactorial 
disorder, a number of important contributing factors have been 
identified over the last 2 0 years. For example, the association 
between serum cholesterol and CHD has well been established [1, 
2, 6] . Other than environmental factors such as smoking and 
alcohol intake, genetic variations play an important role in 
leading to hypercholesterolaemia. 
1.1 LIPID METABOLISM 
The major lipids present in the plasma are fatty acid, 
triglyceride, cholesterol and phospholipid. Cholesterol and 
triglyceride are hydrophobic compounds whereas phospholipid is 
amphipathic, they are integral components of lipoprotein and cell 
membrane. Because lipids are water in-soluble, they are 
transported in blood in association with proteins, for example 
cholesterol and triglyceride circulate in complexes known as 
lipoproteins. These consist of an non-polar core of triglyceride 
and cholesterol ester surrounded by phospholipid, cholesterol and 
protein known as apolipoprotein• Apolipoprotein is important both 
structurally and in the metabolism of lipoprotein. 
Lipoproteins are different in the floatation rate, hydrated 
density, size and electrophoretic mobility. Most often they are 
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separated by ultracentrifugation in the order of increasing 
density, they are chylomicron (CM), very low density lipoprotein 
(VLDL), intermediate density lipoprotein (IDL), low density 
lipoprotein (LDL) and high density lipoprotein (HDL)• 
1.1.1 CHYLOMICRON 
Chylomicron consists mainly of triglyceride and major 
apolipoproteins include apo B-48, apo C and apo E. It transports 
dietary triglyceride (exogenous triglyceride) from intestine to 
sites of utilization. The triglyceride of chylomicron is 
hydrolysed by lipoprotein lipase, located on the luminal surface 
of the capillary endothelium of adipose tissue, skeletal and 
cardiac muscle, free fatty acids are then delivered to these 
tissues either to be used as energy substrates or, after re-
esterification to triglyceride, for storage. While the residual 
particle, called chylomicron remnant, is removed from the plasma 
rapidly in the liver by a specific receptor which has not yet 
been fully characterized. Under normal conditions, the above 
process proceeds rapidly postprandially. 
1.1.2 VERY LOW DENSITY LIPOPROTEIN 
Endogenous triglyceride, synthesized in the liver, is transported 
in VLDL which contains cholesterol, triglyceride, apo B-lOO, 
apo E and apo C. As the surface components are removed, 
triglyceride is hydrolysed by lipoprotein lipase, VLDL is then 
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degraded into IDL. Under normal condition, most IDL particles are 
removed from blood by binding to the LDL receptor in the liver. 
IDL particles have a very high affinity for LDL receptor, 
therefore they have a short lifespan of only a few minutes in 
blood. A fraction of IDL particles escapes hepatic uptake and 
undergoes further lipolysis to generate LDL. 
1.1.3 LOW DENSITY LIPOPROTEIN 
LDL is the main cholesterol carrying particle in plasma. It 
transports cholesterol from the liver to peripheral tissues, LDL 
receptor is also called B/E receptor due to its capability of 
recognizing both apo B and E [1]. LDL can bind to specific LDL 
receptor on cell surface that recognize apo B一 100, the sole 
protein component of LDL. Subsequently, LDL is internalized and 
after lysosomal degradation, free cholesterol is then released. 
When the intracellular cholesterol concentration is increased, 
the activity of hydroxymethylglutarate-Co A (HMG Co-A) reductase, 
the rate limiting enzyme of cholesterol synthesis pathway is 
decreased, the activity of the acyl Co-A cholesterol 
acyltransferase (ACAT) is increased and the LDL receptor is down 
regulated. 
Cholesterol can also be uptaken by cells through non-receptor-
mediated pathway. This may account for two-thirds of cholesterol 
uptake at a 'normal' serum cholesterol and even more at higher 
levels. This uncontrolled uptake of cholesterol is thought to be 
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an important factor in the pathogenesis of atherosclerosis. When 
macrophages become overloaded with cholesterol esters, they are 
converted to ‘foam cells', a major component of atheromatous 
plaque. 
1.1.4 HIGH DENSITY LIPOPROTEIN 
High density lipoprotein, comprising phospholipid, cholesterol, 
apo AI, apo All and apo E as main apolipoproteins are synthesized 
primarily in the liver and, to a lesser extent, in small 
intestinal cells. HDL have an important function in removing 
cholesterol from the circulation by assimilation from cellular 
membrane or through high-density lipoprotein receptor [7, 8, 9, 
10]• Epidemiologic studies have shown a correlation between low 
HDL level and an increased risk of CHD. 
1.2 APOLIPOPROTEIN B 
The metabolisms of plasma lipoproteins are directed by specific 
proteins, called apolipoproteins. Two apolipoproteins, apo E and 
apo B, are ligands that bind LDL receptors on surface of various 
cells. 
Two forms of apo B exist in the plasma : apo B-48 and apo B-100. 
Apo B-48, a truncated forin of approximate 2152 amino acids from 
the amino terminus, is the structural protein moiety of 
chylomicron and its remnant. It is synthesized and secreted with 
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chylomicron in the intestine. It is used for the assembly of 
chylomicron and has an obligatory role in the absorption of 
dietary fats. Due to the rapid turnover of the chylomicron, the 
concentration of apo B-48 in plasma is normally very low. Apo 
B-lOO is the full molecule, a single polypeptide composed of 4536 
amino acids, with a molecular weight of about 513 kilo-Daltons 
(kD)• Only apo B-lOO possesses receptor binding activity and is 
required for the assembly of triglyceride rich VLDL particles in 
the liver. It is also found in IDL and LDL, which are metabolic 
products of VLDL. Majority of the plasma apo B is in the LDL 
fraction [1]. 
1.3 APOLIPOPROTEIN B GENE 
The apolipoprotein B gene resides on the short arm of chromosome 
2 (2p 23-24) [6]. The complete nucleotide sequence for the apo 
B cDNA and the deduced amino acid sequence are reported [5]. 
Apo B gene spans over 4 3 kb and comprises 29 exons and 28 
introns. Exons 26 and 29 are extremely large, 7572 and 1906 bp 
respectively. The apo B-lOO mRNA which is 14.1 kb in length 
coding for a 24-29 amino acid signal peptide and a 4536 amino 
acid mature protein [11]. Apo B-48 is encoded by the same apo B 
gene, however, the inRNA is edited postranscriptionally by a 
tissue specific enzyme [12] which causes a C~U change of codon 
CAA specifying 2153 Gin to a stop codon. Therefore, the apo B-48 
protein comprises 2152 amino acids from the amino terminal [14]• 
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This process occurs mainly in the intestine and to a lesser 
extent in the liver [14]. 
The factors which regulate apo B synthesis and secretion rate are 
not clear. In intestinal and liver cells DNA methylation has been 
suggested to participate in the regulation of apo B gene 
expression. 
1.4 GENETIC VARIATIONS IN HUMAN APO B GENE AND THEIR 
ASSOCIATIONS WITH ABNORMAL LIPID METABOLISM 
The main function of the apo B-lOO is binding to the LDL receptor 
for cellular catabolism of LDL, genetic variation of the apo B 
gene might affect LDL metabolism. 
1.4.1 ABETALIPOPROTEINEMIA 
Abeta1ipoproteinemia is a rare autosomal recessive disorder. The 
disorder is characterized by low levels of plasma cholesterol and 
triglyceride and complete absence of plasma apo B, VLDL, LDL and 
chylomicron. In abetalipoproteinemia all other apolipoproteins 
are found in the HDL fraction. Abetalipoproteinemia is resulted 
from apo B gene mutations that prevent synthesis of apo B or 
produce an aberrant apo B mRNA or protein molecule [14]• 
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1.4.2 HYPOBETALIPOPROTEINEMIA 
Patients homozygous for hypobetalipoproteinemia have been 
described lack of plasma apo B, VLDL, LDL and chylomicron. They 
are phenotyp ica1ly indistinguishable from patients with 
I 
abetalipoproteinemia, the only difference appears to be that 
parents of these patients have half-normal LDL level, whereas 
parents of abetalipoproteinemic patients have normal LDL level. 
1.4.3 FAMILIAL DEFECTIVE APOLIPOPROTEIN B-LOO 
Familial defective apo B-lOO is a genetic disorder characterized 
by elevated plasma LDL cholesterol concentration, and in some 
cases by premature atherosclerosis [15]• DNA sequence analysis 
of the defective allele has shown a CGG-CAG transition at the 
codon specifying amino acid 3500, resulting a Gln-Arg 
substitution [1] . This mutation affects the LDL-LDL receptor 
interaction. 
1.5 POLYMORPHISMS OF APO B GENE 
A number of genetic polymorphisms of apo B gene have been 
reported. [4, 6, 16-«20, 32] . They include: (1) insertion/deletion 
of signal peptide in exon 1, (2) Xbal in exon 26, (3) EcoRI in 
exon 29, • (4) Mspl in promoter site, (5) Mspl at codon 3611, (6) 
StyII in intron 2 and (7) 3' variable number of tandem repeat. 
Some of these polymorphisitis have been found to be associated with 
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serum lipid levels [4], peripheral arterial disease [21], 
coronary artery disease [22, 23] and risk of myocardial 
infarction [24] • However conflicting results were often obtained 
by different studies [X6-20, 22, 24]. 
Among various polymorphisms, the following three were well 
studied: insertion/deletion (I/D) polymorphism of the signal 
peptide in exon 1, Xbal polymorphism (Thr 2488 C to T) in exon 
26 and EcoRI polymorphism (Glu/Lys 4154) in exon 29. 
In exon 1, the deletion allele codes for 24 amino acids, when 
compared with the insertion allele codes for 27 amino acids, 
three amino acids, leu-ala-leu are deleted. The absence of these 
amino acids might alter the hydrophobicity of the signal peptide 
and the rate of translocation of apo B from the cytoplasm into 
the endoplasmic reticulum, then affecting the rate of apo B 
synthesis and secretion. 
Xbal polymorphism in exon 2 6 has been found to be associated with 
variation of cholesterol levels in normal individuals [26-28] and 
patients with familial hypercholesterolaeinia [29]• However the 
underlying mechanism is unknown. Associations between the EcoRI 
polymorphism in exon 29 and coronary heart disease have also been 
reported [22-24,30]. 
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1.6 METHODS FOR DETECTION OF POLYMORPHISMS 
Polymerase chain reaction (PGR) is widely used for the 
amplification of a DNA segment. Polymorphism can be detected by 
various methods with the PGR product. Small deletion and 
insertion at defined location can be detected by size difference 
of the amplified DNA fragments by gel electrophoresis. If the 
polymorphism creates or abolishes a restriction enzyme cutting 
site, it can be identified by digestion of the amplified DNA 
fragments with the appropriate enzyme and then be analyzed by gel 
electrophoresis• 
In the setting up of each PGR protocol, some factors that would 
affect the amplification reaction should be evaluated. These 
include: 
(1) Effect of magnesium chloride concentration in the reaction 
mixture. 
(2) Annealing temperature should be optimized. It is related to 
the melting temperature (TJ of the pair of primers used. Melting 
temperature is estimated from the number of adenosine (A) • 
thymine (T), cytosine (C) and guanine (G) in each DNA primer 
(Tm == [2 X (A + T) + 4 X (C + G) ]°C. The annealing temperature 
should be 4 to 5�C below the Tm. 




1 . To set up a polymerase chain reaction for the detection of 
three polymorphisms of the apo B gene : signal peptide 
insertion/deletion polymorphism in exon 1, Xbal in exon 26 
and EcoRI in exon 29. 
2. To determine the allelic distribution frequenies of the 
three polymorphisms of the apo B gene in cord blood samples 
and geriatric Chinese in Hong Kong. 
3. To correlate the three polymorphisms of the apo B gene and 
serum lipid levels among geriatric Chinese in Hong Kong. 
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3. MATERIALS AND METHODS 
3.1 MATERIALS AND EQUIPMENTS 
3.1.1 ENZYMES 
Taq DNA polymerase was obtained from GIBCO-BRL, Life 
Technologists, Inc., Gaithersburg, USA. Two restriction enzymes 
EcoRI (20,000 U/xnL) and Xbal (20,000 U/mL) were purchased from 
New England Biolabs, Beverly, USA. 
3.1.2 DNA MARKERS 
Haelll digested pBR3 2 2 DNA was purchased from Sigma Chemical Co., 
St. Louis, USA. 1 Kb lambda DNA was obtained from GIBCO-BRL, Life 
Technologies, Inc., Gaithersburg, USA. 
3.1.3 GENERAL REAGENTS 
All reagents used were either of biochemical or AR grade. 
Agarose, dimethyl sulphoxide and ethidium bromide were obtained 
from Sigma Chemical Co. , St Louis, USA. Bromophenol blue and 
paraffin liquid were purchased from E. Merk, Darmstadt, Germany. 
3.1.4 EQUIPMENTS 
Perkin Elmer Cetus Thermal cycler 480 was purchased from Perkin 
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Elmer Co., Norwalk, USA. Electrophoresis tank, model horizon 
11.14 was bought from GIBCO-BRL, Life Technologies, Inc., 
Gaitherstairg, USA. UV~Transilluminator model TS-36 with polaroid 
camera was purchased from Ultraviolet Product, Inc., USA. DNA 
synthesizer Cyclone Plus was purchased from Millipore Co., 
Bedford, USA. ACS 180 was purchased from Ciba Corning Diagnostic 
Cop., Medfield, USA and Dimension AR was purchased from Dupont 
Medical Products, Wilmington, USA. Cobas Mira was purchased from 
F. Hoffmann-La Roche & Company, Baole, Switzerland. 
3.2 BUFFERS 
10 X TAE buffer used was 0.4 M Tris-BASE and 0.001 M EDTA in 
distilled water and pH of 7.4. 10 X Polmix buffer was 500 mM 
potassium chloride (KCl), 100 mM Tris-HCl, 0.01 % gelatin and 
2 mM each of deoxynucleotide triphosphate (dNTP) in distilled 
water. Gel loading buffer was 0.25% (v/w) bromophenol blue and 
15% (v/v) Ficoll in distilled water. 
3.3 AGAROSE GEL ELECTROPHORESIS 
Horizontal agarose gel electrophoresis was carried out on a gel 
electrophoresis tank. Agarose gel was prepared in 1 X TAE buffer. 
The slurry was heated in a microwave oven until complete 
dissolution. Ethidium bromide (10 mg/mL) was added to give a 
final concentration of 0.5 ug/mL. Then the gel was poured into 
an electrophoresis tray for solidification. Comb was placed 
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immediately, the teeth of which would form the sample wells. 
After setting of the gel, the comb was removed carefully and the 
gel was put in the electrophoresis tank. Enough 1 X TAE buffer 
was added into the tank to cover the gel surface [31] • DNA marker 
and samples mixed with loading buffer were loaded into the sample 
wells of the gel. Electrophoresis was then carried out by running 
at 50-100 itiA until the bromophenol blue migrated to the desired 
distance on the gel. After electrophoresis, the gel was viewed 
on the UV transilluminator and photograph taken under UV light 
with Polaroid film. 
3.4 STUDY SUBJECTS 
3.4.1 CORD BLOOD SAMPLES 
Cord blood samples in EDTA tubes were collected from normal 
deliveries of Chinese babies in Hong Kong. Genomic DNA was 
extracted. 
3.4.2 GERIATRIC SUBJECTS 
CASES 
Patients recruited into this group included 12 women and 6 men 
aged 60-80 with high total cholesterol (> 6.2 mmoL/L) and LDL 
cholesterol (> 4.1 mmoL/L). Patients fulfilled the selection 
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criteria with known secondary causes of hyperlipidaemia such as 
diabetes mellitus and hypothyroidism but well controlled were 
also included. 
CONTROLS 
The control group included 18 women and 6 men aged 57-87 with 
normal serum lipids levels, their total cholesterol and LDL 
-t-
cholesterol were below 6.2 and 4.1 mmoL/L respectively. 
Reference intervals of serum lipid are listed in Appendix I. 
3.5 CLINICAL DATA 
Weight and height of each subject were measured. Body mass index 
(BMI) was then calculated [Weight (Kg) / Height^ (m^ ) ] . History 
of smoking, alcohol and drug intake were also recorded. 
3.6 BLOOD COLLECTION 
Fasting blood was collected from each subject by venepuncture 
into EDTA tube for DNA study, heparin tube for biochemical 
analysis, plain tube for thyroid function test and fluoride tube 
for glucose analysis. 
The EDTA blood tubes were stored at -2 0°C for not more than 3 
months prior to DNA extraction. Plasma and serum were separated 
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as soon as possible for biochemical analysis. 
3.7 BIOCHEMICAL ANALYSIS 
Thyroid function test was performed on ACS 180 (Ciba Corning 
Diagnostic Cop., Medfield, USA). Renal function test, liver 
function test, lipid profile, cardiac enzymes, uric acid and 
gamma glutamyl transferase were performed on Dimension AR (Dupont 
Medical Products, Wilmington, USA)• Plasma glucose was done on 
Cobas Mira (F. Hoffmann-La Roche & Company, Baole, Switzerland). 
All the biochemical tests were carried out according to the 
manufacturer's procedures. HDL cholesterol was measured using the 
supernatant after phosphotungstate magnesium precipitation. LDL 
cholesterol was calculated using the Friedewald formula (LDL 
cholesterol = Total cholesterol - HDL cholesterol -
Triglyceride/2.3). 
3.8 DNA EXTRACTIONS 
Salting out method [37] was used to extract DNA from thawed EDTA 
blood. 
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3.9 POLYMERASE CHAIN REACTION (PGR) 
The PGR protocols were modified from reference 20. 
OLIGONUCLEOTIDE PRIMERS 
Oligonucleotide primers were synthesized on a DNA synthesizer. 
Cyclone Plus 480 (Millipore Co., Bedford, USA). Sequences of the 
5' upstream and 3 ‘ downstream primers and their corresponging 
positions on cDNA of the apo B gene were shown in Table 1. 
Amplification was carried out in a final volume of 50 ul 
containing 200 ng of genomic DNA, 250 ug of each primer, 10% 
dimethyl sulphoxide (DMSO), 5 uL 10 X Polmix buffer and 0.5 units 
of Taq DNA polymerase. The reaction mixture was topped with 50 
uL of liquid paraffin to prevent evaporation, 
A water blank with the composition as the sample tube except the 
genomic DNA was run in parallel to check for contamination. 
The amplification was performed on a Perkin Elmer Cetus Thermal 
Cycler (Perkin Elmer Co., Norwalk, USA.). 
SIGNAL PEPTIDE INSERTION/DELETION POLYMORPHISM 
In the study of insertion/deletion (I/D) of signal peptide in 
exon 1, fragments of 93/84 base pairs (bp) were amplified in a 
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reaction mixture with 1.0 mM MgCl�，under the conditions of 40 
cycles of denaturation at 9 5�C for 1 minute and annealing at 65�C 
for 1.5 minutes without extension period. 
The PGR product (10 uL) was analysed on a 5% agarose gel at a 
current of 100 mA for 45 minutes. Hae III digested pBR322 was 
used as marker. 
-i-
Xbal POLYMORPHISM 
The Xbal polymorphism was analyzed by amplifying a 710 bp 
fragment in a reaction mixture of 3.0 mM MgClj. The condition for 
amplification was an initial denaturation period of 5 minutes at 
95�C, followed by 35 cycles of denaturation at 95�C for 1.5 
minutes, annealing at SS^'C for 2 minutes and extension at 72�C for 
3 minutes. Finally an extra extension period of 5 minutes at 72�C 
was carried out. 
Ten uL of PGR products was checked in 1% agarose gel, run at a 
current of 100 mA for one hour with 1 Kb lambda as marker. Then 
overnight digestion of the PCR product with 10 U of Xbal at 37�C 
resulted in fragments of 43 3 bp and 277 bp in the presence of 
cutting site. Electrophoretic separation of 10 uL of the digested 
PCR products was performed on 2.5% agarose gel at a current of 
100 mA for one hour with 1 Kb lambda as marker. 
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EcoRI POLYMORPHISM 
For analysis of the EcoRI polymorphism, a fragment of 480 bp was 
amplified in a reaction mixture with 1.0 itiM MgClj. The PGR 
program was carried out by initial denaturation at 95°C for 5 
minutes, followed by 35 cycles of denaturation at 95�C for 1.5 
minutes, annealing at 55°C for 2 minutes and extension at 72°C for 
3 minutes. Finally, an extra extension period of 5 minutes at 
72�C was carried out. 
Ten uL of amplified product (480 bp) was checked on a 2% agarose 
gel electrophoreted at a current of 100 mA for one hour using 1Kb 
lambda as marker. Overnight digestion of the PGR products with 
10 U of EcoRI at 3 7�C gave 253 bp and 227 bp fragments in the 
presence of the cutting site. Agarose gel electrophoresis of 
10 uL of the digested PGR product was then performed in 3% 
agarose gel at a current of 100 mA for one hour. 
3.10 DATA ANALYSIS 
The allelic frequencies of the three polymorphisms in the cord 
blood samples, case and control groups were estimated by gene 
counting method. The significance of the differences of allelic 
frequencies between groups was tested by chi-square test. The 
significance of differences between the lipid levels and 
demographic data in different groups were estimated by students‘ 
t-test. Analysis of variances (ANOVA) with sex, age and BMI as 
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covariates was performed to estimate the percentage of sample 
variance (R^  x 100) of serum lipids which could be explained by 
each of the apo B gene polymorphisms. Data on ANOVA were not 
presented as none of the tested polymorphisms reached the 
required level of significance (p < 0.05). All the statistical 




4.1 OPTIMIZATION OF PGR 
PCR protocols for the three polymorphisms were optimized by 
studying the magnesium concentration in the PCR buffer and 
annealing temperature in the PCR temperature program. Results of 
the investigations on the PCR of the EcoRI and signal peptide 
insertion/deletion site were shown in Fig. 1 and 2 respectively. 
The bands with the highest light intensity represented the best 
PCR production. The results appeared the best at a magnesium 
concentration of 1.0 mM and an annealing temperature of 65�C on 
the PCR protocol of the signal peptide insertion/deletion site. 
In the PCR protocol for studying Xbal polymorphism on exon 26 and 
Eco RI polymorphism on exon 29, the magnesium concentration was 
3,0 and 1.0 mM respectively and annealing temperature were both 
of 55�C. 
4.2 CLINICAL FEATURES OF THE CASE AND CONTROL SUBJECTS 
Both groups of subjects had similar proportion of males and 
females (Table 2). They also have statistically comparable age, 
height, weight and body mass index (BMI) according to the 
students‘ t-test. The case subjects had significantly higher 
serum levels of total cholesterol (TC), triglyceride (TG), 
LDL-cholesterol (LDL-C) and lower HDL-cholesterol (HDL-C) than 
the control subjects (Table 2�. 
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4.3 GENOTYPING 
The allelic frequencies of the three polymorphic sites, I and D 
(the insertion and deletion alleles respectively of the signal 
peptide insertion/deletion site), X- and X+ (the alleles 
corresponding to the absence and presence respectively of the 
Xba I site in exon 26) and E+ and E- (the alleles corresponding 
to the presence and absence respectively of the Eco RI site of 
exon 29) obtained in the cord blood samples were consistent with 
reported values in the literature (Table 3) . They generally 
agreed with the Hardy-Weinberg equilibrium. The only exception 
was the allelic frequencies of the signal peptide region of the 
female cord blood samples in that there was small statistical 
difference (p < 0.05, chi-square test) between the actual and the 
expected frequencies (Table 3). The female and male cord blood 
samples agreed in their allelic frequencies. Therefore the 
results of all the cord blood samples were used for comparison 
with control and case subjects. 
Two of the rare alleles, D and E- were found to be of 
surprisingly high frequencies in the control subjects (Table 4) • 
They were even statistically higher than those of the case 
subjects, 0.312 vs 0.267 and 0.413 vs 0.067 respectively, and 
higher than those of the cord blood samples, 0.312 vs 0.181 and 
0.413 vs 0.061 respectively. The other rare allele, X+, was 
infrequent in the control subjects (0.042) and in the cord blood 
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samples (0.061) and was absent in the case subjects. It is noted 
that the cord blood samples resemble the case subjects more than 
the controls in allelic distributions of the three polymorphic 
sites. 
Case subjects having the ID genotype did not show any significant 
difference in serum levels of any of the lipids from those of the 
II genotype (Table 5)• In the control subjects, the ID genotype 
did result in lower TC, TG and LDL-C. The DD genotype, however, 
reversed the effect (Table 5)• 
No X+ allele was detected in the case subjects and there were two 
control subjects with the X-X+ genotype (Table 6) • These two 
controls had higher TG and correspondingly lower HDL-C when 
compared with the other control subjects having the X-X -
genotype. 
No E-E- genotype was detected in both control and case subjects 
but the relative frequencies of the E+E+ and E-E+ genotypes were 
reversed in the two subject groups. The effects of the rare 
allele E- on the serum lipid levels were conflicting. Presence 
of E- resulted in higher TC, TG and LDL-C and lower HDL-C in the 
case subjects but the effects were reversed in the control 
subjects (Table 7). It is noted that the control subjects having 
the E+E- genotype actually had lower TC and LDL-C than those 
having the E+E+ genotype. 
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5. DISCUSSION 
5.1 OPTIMIZATION OP PGR PROTOCOLS 
The polymerase chain reaction (PGR) has become a popular research 
technique, mainly because of its effectiveness and reliability 
in in vitro amplification. However the success of a PGR depends 
on stringent reaction conditions. To set up a PGR protocol, an 
optimization procedure is always required. 
Magnesium concentration and temperature program were the two 
reaction conditions evaluated during the optimization of each PGR 
protocol in this study. Magnesium concentration of about 1.5 mM 
with 200 uM each deoxynucleotide triphosphate (dNTP) are commonly 
used [32], however, in some circumstances, different amount of 
magnesium may be necessary. In this study, effects of magnesium 
concentration at 1.0, 2.0, 3.0 and 4.0 mM in PGR buffer were 
investigated in each PGR protocol. Excess magnesium will result 
in non-specific amplification while insufficient of which will 
reduce the yield [32]. A magnesium concentration of 1 mmoL/L was 
found to be optimal for the two PGR protocols (study of signal 
peptide insertion/deletion and EcoRI polymorphisms) in this 
study. But in the PGR protocol for the study of Xbal 
polymorphism, the optimal concentration was 3.0 mmoL/L. 
Temperature program greatly affect the result of a PGR. The 
denaturation temperature is usually between 90-95°C for complete 
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denaturation of double stranded DNA. The annealing temperature 
that affects the annealing of their complementary sequences on 
the template and therefore affect the specificity and yield of 
the reaction. Usual annealing temperatures are 4 to 5�C below the 
melting temperatures of the primers. The annealing temperatures 
of the three PCR protocols in this study were all below the 
melting temperature of the corresponding primers. Finally the 
extension time is related to the length of target DNA fragment 
to be amplified. The extension step can be eliminated if the 
target sequence is approximately 150 bases or less [36]. In this 
study the extension step was omitted in the PCR of the signal 
peptide insertion/deletion polymorphism of apo B gene, in which 
the amplified DNA fragments were 84 and 93 bp. 
5.2 CLINICAL DATA 
Age and BMI are the two important covariants that will influence 
the investigation of the association of the three polymorphisms 
of apo B gene with hyperlipidaemia [20] . As there were no 
significant differences of these two parameters between the two 
groups and test of ANOVA with these two parameters of the 
polymorphisms did not reach the required level of significance 
(p < 0.05), the test of associations of the three polymorphisms 
of apo B with hyperlipidaemia could simply be carried out without 
considering these covariants. 
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5.3 ALLELIC FREQUENCIES OF THE THREE POLYMORPHISMS OF APO B 
GENE 
There was no sex difference in the frequencies of the rare 
alleles: the D allele (deletion allele), the X+ allele (presence 
of the Xba I site) and E- allele (absence of the Eco RI site)• 
The frequencies of the rare alleles (D at 0.181, X+ at 0.061 and 
E- at 0.061) were similar to those previously reported in the 
Chinese control samples [20] (D at 0.207, X+ at 0.091 and E- at 
0.071). Therefore, the cord blood samples can be used to obtain 
reference genotypic patterns of the apolipoprotein B gene in the 
Chinese population in Hong Kong. 
The rare alleles D and E~ are known to be associated with high 
serum lipid levels [6, 20] . However, in this study their 
frequencies are found to be higher in the control subjects than 
in the case subjects who were hyperlipidaemic. Although the 
relatively small number of subjects in this study may not truly 
reflect the actual relationship, it is possible that the 
phenotypic expression of those genes may interact with the other 
genes and the environment to alter the pattern of serum lipid 
levels. The pattern of the frequency distribution of the genotype 
of the insertion/deletion region (II, ID, DD) and of the Xb I 
site (X-X-, X-X+, X+X+) were similar between the controls and 
the cord blood samples, but were different with the case subjects 
which indicated that the case subjects might associate with some 
genetic defects in these two regions. The genotypic pattern of 
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the EcoRI site (E+E+, E+E-, E-E-） was different between the 
control and the cord blood samples, but similar between the 
latter and the case subjects, reason was again unclear. There 
were no X+X+ genotype detected in both controls and cases, the 
only X+ allele found was in two X-X+ control subjects because the 
frequency of the X+ allele in the Chinese is very low. 
5.4 ASSOCIATION OF POLYMORPHISMS OF APO B GENE WITH THE CASE 
GROUP 
If an apo B gene polymorphism contribute to the increased level 
of total cholesterol, triglyceride, LDL cholesterol and decreased 
level of HDL cholesterol, one would expect a difference in allele 
frequencies at the apo B gene locus between the case and control 
groups. However, results of this study showed no significant 
difference in allele frequencies at the three polymorphic sites 
(signal peptide ins/del in exon 1, Xbal in exon 26 and EcoRI in 
exon 29) between the case and control subjects. May be the 
numbers of subjects in the two groups were too small to achieve 
significant statistical differences. 
5.5 ASSOCIATION OP POLYMORPHISMS OF APO B GENE WITH 
HYPERLIPIDAEMIA 
SIGNAL PEPTIDE INSERTION/DELETION POLYMORPHISM 
Signal peptide alterations have two profound effects: decrease 
36 
the efficiency of export and alter protein processing [19]. These 
alterations may affect the encoded information, folding and the 
hydrophobicity of the leader peptide [26] . Each of them have a 
role in membrane translocation and consequently on apo B 
synthesis and secretion. The D allele is characterized by the 
absence of three amino acids, leu-ala-leu, when compared with the 
I allele. The absence of these amino acids alters the 
hydrophobicity of the signal peptide. Therefore, this effect 
could alter the rate of translocation of apo B from the cytoplasm 
into the endoplasmic reticulum. Consequently, the rate of 
secretion of apo B from hepatocytes in the form of LDL would be 
different, which would directly affect the serum levels of LDL 
cholesterol [19]. 
However, presence of the D allele in this study did not correlate 
with an increase in serum lipid levels in both control and case 
subjects. But a correlation existed in the Chinese control 
samples [6], in which D allele correlated strongly with increased 
level of total cholesterol. 
As there is exchange of cholesteryl esters between LDL and HDL 
particles which is mediated by cholesteryl ester transfer protein 
(CETP) [36], a mutation in the apo B gene which affected this 
exchange could lead to lower levels of HDL cholesterol. 
Therefore, if this second mutation is in linkage disequilibrium 
with the signal peptide insertion/deletion polymorphism, the 
association of D allele with low levels of HDL cholesterol found 
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9-
in the control group could be possible. 
Xbal polymorphism 
Correlation of the X+ allele of the Xbal polymorphism with higher 
levels of total cholesterol has been reported in several 
populations of European origin [22, 26-28]. In this study, the 
X+ allele was found to correlate with high levels of triglyceride 
and in particular low levels of HDL cholesterol only in the 
control subjects. This corresponds with a study of association 
of apolipoprotein B gene polymorphisms with lipid levels in men 
of South Asian descent [20]. The mutation that creates the Xbal 
restriction site does not create a change in the amino acid 
residue at 2488, so it is unlikely to affect lipid metabolism 
directly. The Xbal polymorphism was therefore presumed to be a 
marker in linkage disequilibrium with a functional mutation in 
the apo B gene itself or in the neighbouring sequence that 
affects cholesterol levels. 
The correlation of X+ allele with low level of HDL cholesterol 
could be explained by second mutation which is in linkage 
disequilibrium with the Xbal polyraorphism. The most common 
mutation found was that affect the exchange of cholesteryl ester 
with LDL and HDL particles mediated by CETP as described before 
in the signal peptide insertion/deletion polymorphism. 
EcoRI polymorphism 
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Case subjects having the E+E- genotype had higher total serum 
cholesterol, triglyceride and LDL-cholesterol but lower HDL-
cholesterol than those case subjects having the E+E+ genotype. 
In the control subjects, such relationships were reversed. 
Actually many studies revealed a positive correlation of E-
allele with coronary artery disease only but not serum lipid 
levels [6, 16, 20, 22-24]. 
"i-
5.6 CONCLUSION 
There was no conclusive correlation of apo B polymorphism with 
serum lipids levels. The view that presence of the D and the X+ 
alleles was associated with increase in serum cholesterol levels 
was not affirmed by the results of this study. The conflicting 
effects of the E- allele on the lipid levels in the controls and 
cases cast a question on a positive relationship between E- and 
serum cholesterol. 
A number of explanations for the lack of consistency in the 
association between the three apo B gene polymorphisms with serum 
lipid levels among the two study subjects could be suggested. 
Firstly, lipid metabolism is determined by more than one gene. 
Interactions between these genes can differ between individuals 
of the same population. Secondly, phenotypic expression of those 
genes may depend on interactions between the genes and the 
environment, which may result in one allele being associated with 
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hyperlipidaemia in one environment and other allele of the same 
gene associated with hyperlipidaemia in another environment. 
Thirdly, influences of factors such as diet and exercise on serum 
lipid levels of each individual could be important. Lastly, the 
sample size of both groups was small (case : 15, control : 24) 
that may not be able to achieve significant differences 
statistically. In addition, the frequencies of the rare alleles 
(D, X+ and E-）in the Chinese population are low, it was very 
difficult to reveal true and weak association between them with 
serum lipids levels. 
I 
Other than the signal peptide insertion/deletion, Xbal and EcoRI 
polymorphisms, there are some other known polymorphisms in apo 
B gene may associate with coronay heart disease or lipid levels. 
More studies enclosing more polymorphisms together with much 
larger sample size may be useful in understanding the full 
picture of association of apo B gene polymorphisms with serum 
lipid levels. 
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Fig. 1 : Effect of magnesium concentration on the PGR of 
EcoRI polymorphism of apo B gene of 4 cord blood 
samples. 
Lane 1 : pBR32 2 DNA marker 
Lane 2 - 5 : Sample 1 
Lane 6 - 9 : Sample 2 
Lane 10-13 : Sample 3 
Lane 14-17 : Sample 4 
Lane 18 : water control 
Lane 19 ： 1 Kb lambda DNA marker 
Lane 2, 6, 10 and 14 : 1.0 mM MgClj 
Lane 3, 7, 11 and 15 : 2.0 mM MgClj 
Lane 4, 8, 12 and 16 : 3.0 mM MgClj 
Lane 5, 9, 13 and 17 : 4.0 mM MgClj 
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Fig. 2 : PCR of insertion/deletion polymorphism of signal 
peptide of apo B gene of 15 cord blood samples 
under correct annealing temperature (65®C) 
Lane 1, 18 : pBR322 DNA marker 
Lane 2 - 1 6 : Cord blood samples 
Lane 17 : water control 
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Fig. 3 : Gel electrophoresis of 15 cord blood samples to 
illustrate the genotypes at the signal peptide 
insertion/deletion (I/D) polymorphic site in exon 
1 of apo B gene. Size of PCR products were given 
in base pairs. 
Lane 1, 18 : pBR3 2 2 DNA marker 
Lane 2, 4, 6-15 : 11 genotype 
Lane 3, 5 : DD genotype 
Lane 16 : ID genotype 
Lane 17 : water control 
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Fig. 4 : Gel electrophoresis of 15 cord blood samples to 
illustrate genotypes at the Xbal polymorphic site 
in exon 2 6 of apo B gene [ + , - referring to 
presence, absence of cutting site for restriction 
enzyme Xba I (X) ] . Size of PGR products were 
given in base pairs. 
Lane 1 : 1Kb lambda DNA marker 
Lane 2-12, 15 : X-/X- genotype 
Lane 13, 14 : X+/X- genotype 
Lane 16 : X+/X+ genotype 
Lane 17 : water control 
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Fig. 5 : Gel electrophoresis of 12 cord blood samples to 
illustrate genotypes at the EcoRI polymorphic 
site in exon 29 of apo B gene [+, - referring to 
presence, absence of cutting site for restriction 
enzyme Eco RI (E) ] • Size of PGR products were 
given in base pairs. 
Lane 1, 14 : 1Kb lambda DNA marker 
Lane 2, 4-11, 13 ; E+/E+ genotype 
Lane 3 : E-/E- genotype 





































































































































































































































































































































































































































Table 2 ： Clinical features of case and control Chinese 
geriatric subjects [Mean(SD)] 
Case Control 
Number of subjects 15 24 
Male / Female 3 / 1 2 6 / 1 8 
Age (years) 69.3 (6.70) 69.2 (8.52) 
Height(cm) 152.3 (8.02) 154.9 (9.90) 
Weight (Kg) 56.6 (11.31) 57.9 (10.88) 
BMI (Kg/in2) 24 . 3 (3 .29) 23.6 (3.92) 
# TC (mmoL/L) 7.97 (0.74) 5.55 (1.08) 
# TG (mmoL/L) 2.49 (1.34) 1.56 (0.98) 
# HDL-C (itimoL/L) 1.23 (0.35) 1.39 (0.59) 
# LDL-C (mmoL/L) 5.84 (0.85) 3.35 (1-22) 
* p < 0.05, # p < 0.01 by students' t-test. 
Abbreviations- BMI: Body Mass Index, TC: Total cholesterol, TG: 
Triglyceride, LDL-C: LDL cholesterol, HDL-C: HDL cholesterol, NS: not 
significant. 
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Table 3 ： Frequency distributions of polymorphisms : signal 
peptide insertion/deletion (I/D), Xbal and EcoRI 
polymorphisms in apo B gene of the cord blood 
samples. 
Female Male Total 
RFLP Genotype O E O E O E 
Signal Peptide II * 41 * (38.7) 39 (39.3) 80 (77.8) 
insertion/ ID * 13 * (18.2) 17 (16.1) 30 (34.4) 
deletion DD * 5 * (2.1) 1 (1.6) 6 (3.8) 
Total 59 (59.0) 57 (57.0) 116(116.0) 
Allelic I 0.810 0.830 0.819 
Frequency D 0.190 0.170 0.181 
Xba I X-X- 51 (50.3) 52 (52.1) 103(102.4) 
X-X+ 7 (8.4) 5 (4.8) 12 (13.2) 
X+X+ 1 (0.3) 0 (0.1) 1 (0.4) 
Total 59 (59.0) 57 (57.0) 116(116.0) 
Allelic X- 0.924 0.956 0.939 
Frequency X+ 0.076 0.044 0.061 
Eco RI E+E+ 51 (51.1) 52 (51.3) 103(106.5) 
E+E- 8 (7.7) 4 (5.3) 12 (9.1) 
E-E- 0 (0.2) 1 (0.4) 1 (0.4) 
Total 59 (59.0) 57 (57.0) 116(116.0) 
Allelic E+ 0.932 0.947 0.939 
Frequency E- 0.068 0.053 0.061 
* p < 0.05, compare significance of difference between observed and expected 
number of samples by chi-square test. 
Abbreviations- O: observed number of samples, E: expected number of samples, 
I: signal peptide insertion allele, D: signal peptide deletion allele, +: 
presence of cutting site for specific restriction enzyme, -: absence of 
cutting site for specific restriction enzyme, E: Eco RI, X: Xba I, RFLP: 
restriction fragment length polymorphism. 
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Table 4 ： Frequency distributions of polymorphisms : signal 
peptide insertion/deletion (工/D), Xbal and EcoRI 
polymorphisms in apo B gene of the case and 
control Chinese geriatric subjects 
Case Control 
RFLP Genotype O E O E p 
Signal Peptide 11 7 (8.0) 12 (11.4) 
insertion/ �. ID 8 (5.9) 9 (10.2) 
deletion DD 0 (1.1) 3 (2.4) 
Total 15 (15.0) 24 (24.0) 
Allelic I 0.733 0.688 NS 
Frequencies D 0.267 0.312 
Xbal X-X- 15 (15.0) 22 (22.0) 
X-X+ 0 (0.0) 2 (2.0) 
X+X+ 0 (0.0) 0 (0.0) 
Total 15 (15.0) 24 (24.0) 
Allelic X- 1.000 0.958 NS 
Frequencies X+ 0.000 0.042 
EcoRI E+E+ 13 (13.0) 4 (7.9) 
E+E- 2 (2.0) 19 (11.2) 
E-E- 0 (0.0) 0 (0.0) 
Total 15 (15.0) 23 (23.0) 
Allelic E+ 0.933 0.587 NS 
Frequencies E- 0.067 0.413 
p value for significance of difference of allele frequencies between case and 
control geriatric Chinese by chi-square test. 
Abbreviations- O: observed number of samples, E : expected number of samples, 
I: signal peptide insertion allele, D: signal peptide deletion allele, +: 
presence of cutting site for specific restriction enzyme, absence of 
cutting site for specific restriction enzyme, E: EcoRI, X: Xbal, RFLP: 
restriction fragment length polymorphism, NS: not significant. 
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Table 5 ： Serum lipids levels (mmoL/L) in relation to three 
genotypes of signal peptide insertion/deletion 
polymorphism of apo B gene in the case and 
control Chinese geriatric subjects [Mean] 
[(SD)] 
Subject Genotype n TC TG LDL-C HDL-C 
Case II 7 7.89 2.70 5.73 1.20 
(0.45) (1.72) (0.74) (0.37) 
ID 8 8.04 2.35 5.91 1.26 
(0.96) (1.05) (0.96) (0.31) 
Control II 12 5.78 1.47 # 3.85 #* 1.51 #@ 
(1.14) (1.00) (1.07) (0.52) 
ID 9 5.19 # 1.27 # 3.11 1.51 
(1.11) (0.75) (0.96) (0.60) 
DD 3 5.70 2.79 # 3.37 1.06 • 
(0.50) (0.87) (1.00) (0.10) 
* p < 0 .05, # p < 0.01, (§: not significant by students' t-test. 
Abbreviations- n: number of samples, TC: Total Cholesterol, TG: Triglyceride, 
LDL-C: LDL-Cholesterol, HDL-C: HDL-Cholesterol, I: signal peptide insertion 
allele, D: signal peptide deletion allele. 
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Table 6 ： Serum lipids levels (mmoL/L) in relation to two 
genotypes of Xbal polymorphism of apo B gene in 
the case and control Chinese geriatric subjects 
[Mean] 
[(SD)] 
Subject Genotype n TC TG LDL-C HDL-C 
Case X-X- 15 7.97 2.49 1.23 5.84 
(0.74) (1.36) (0.85) (0.31) 
X-X+ 0 - - -
Control X-X- 22 5.56 1.52 # 3.49 1.50 # 
(1.13) (1.03) (1.08) (0.52) 
X-X+ 2 5.40 2.01 # 3.60 0.88 • 
(0.85) (0.30) (0.57) (0.11) 
# p < 0.01 by students' t-test. 
Abbreviations- TC: Total Cholesterol, TG: Triglyceride, LDL-C: LDL-
Cholesterol, HDL-C: HDL-Cholesterol, +,- referring to presence or absence of 
cutting site for restriction enzyme Xbal, X: Xbal. 
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Table 7 : Serum lipids levels (mmoL/L) in relation to two 
genotypes of EcoRI polymorphism of apo B gene 
in the case and control Chinese geriatric 
subjects [Mean] 
[(SD)] 
Subject Genotype n TC TG LDL-C HDL-C 
Case E+E+" 13 7.92 * 5.72 * 5.72 # 1.29 # 
(0.72) (0.97) (0.76) (0.29) 
E+E- 2 8.30 * 7.40 * 7.40 # 0.88 # 
(0.99) (3.37) (0.01) (0.24) 
Control E+E+ 4 5.85 # 2.37 # 3.68 # 1.11 # 
(0.60) (1.16) (0.50) (0.14) 
E+E- 20 5.45 # 1.36 # 3.44 # 1.54 # 
(1.16) (0.94) (1.07) (0.58) 
* p < 0.05, # p < 0.01 by students' t test. 
Abbreviations- TC: Total Cholesterol, TG: Triglyceride, LDL-C: LDL-
Cholesterol, HDL-C: HDL-Cholesterol, +, - referring to presence of absence of 




(Chemical Pathology Laboratory 
Prince of Wales Hospital) 
Total Cholesterol < 5.2 mmoL/L Desirable 
5.2 一 6.2 mmoL/L Borderline High 
> 6.2 mmoL/L High 
Triglyceride < 2 . 0 minoL/L Desirable 
HDL Cholesterol > 1.2 mmoL/L (F) Desirable 
> 1.0 mmoL/L (M) Desirable 
LDL Cholesterol < 3.4 mmoL/L Desirable 
3.4 - 4.1 mmoL/L Borderline High 
>4.1 mmoL/L High Risk 
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APPENDIX II 
CALCULATION OF EXPECTED NUMBER OF SAMPLES 
(Take female cord blood samples of signal peptide 
insertion/deletion polymorphism of apo B gene as an example) 
Genotype Number of Number of allele Total number 
samples I D of alleles 
II 41 82 -
ID 13 13 13 -
DD 5 10 -
Total 59 95 23 118 




Expected number of samples 
Let X be the frequency of I allele and y be the frequency of D 
allele 
Number of 工 allele 95 
； ; 5 tmm mm mam mm mmm mm mm tmm mm mm mmm mmm mm> w mm mmm *mm ^^^ mm mm Z^Sl • Q ^^ 
Total number of alleles 118 
Number of D allele 23 
y = 0.19 
Total number of alleles 118 
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Expected number of II genotype = x^  (number of samples) 
= (0.81)2 (59) = 38.7 
Expected number of ID genotype = 2xy (number of samples) 
= 2(0.81)(0.19)(59) 
== 18.2 
Expected number of DD genotype = y^  (number of samples) 
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